Ocugen

Ocugen is a clinical stage biopharmaceutical company.

Ocugen is a clinical stage biopharmaceutical company developing novel treatments for sight threatening diseases including ocular graft versus host disease, retinitis pigmentosa, geographic atrophy, wet age-related macular degeneration and diabetic retinopathy. Ocugen has a broad pipeline which includes both clinical stage and pre-clinical programs addressing large areas of unmet medical need. Their programs are focused on activating novel biologic pathways to treat inflammatory, degenerative, and neovascular diseases of the eye and are designed to deliver value over the near, mid and long term.